Retatrutide and blood pressure — need advice

roxy_nash said:

KevinCompounds said: ...cardiovascular risk is just another fad...

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

Dr.PainCLE said:

Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.

That reframing is the part I needed. I will report back once I have actually tried it.

roxy_nash said:

KevinCompounds said: ...cardiovascular risk is just another fad...

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Dr.RenalNash said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

6 month update on cardiovascular risk: down 56 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Carry on.